Cargando…

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases

BACKGROUND: We previously demonstrated the safety of stereotactic body radiotherapy followed by pembrolizumab (SBRT+P) in patients with advanced solid tumors. This phase I clinical trial was expanded to study the safety of partial tumor irradiation (partial-Rx). We assessed irradiated local failure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korpics, Mark C., Onderdonk, Benjamin E., Dadey, Rebekah E., Hara, Jared H., Karapetyan, Lilit, Zha, Yuanyuan, Karrison, Theodore G., Olson, Adam C., Fleming, Gini F., Weichselbaum, Ralph R., Bao, Riyue, Chmura, Steven J., Luke, Jason J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178837/ https://www.ncbi.nlm.nih.gov/pubmed/37183819 http://dx.doi.org/10.1172/JCI162260

Ejemplares similares

The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond
por: Onderdonk, Benjamin E., et al.
Publicado: (2019)

Beyond the Expectation: Pembrolizumab-Associated Tumor Lysis Syndrome in Metastatic Gastric Adenocarcinoma
por: Battah, Arwa, et al.
Publicado: (2023)

Immunogenicity of pembrolizumab in patients with advanced tumors
por: van Vugt, Marianne J. H., et al.
Publicado: (2019)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab
por: Wu, Meng, et al.
Publicado: (2021)

Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes
por: Karapetyan, Lilit, et al.
Publicado: (2023)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
por: Godfrey, James, et al.
Publicado: (2022)

Tumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
por: Bari, Omar, et al.
Publicado: (2017)

The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance
por: Canar, Jorge, et al.
Publicado: (2023)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
por: Garassino, Marina C., et al.
Publicado: (2022)

Nanomedicine for Combination Therapy of Cancer
por: He, Chunbai, et al.
Publicado: (2015)

Tumor-reprogrammed resident T cells resist radiation to control tumors
por: Arina, Ainhoa, et al.
Publicado: (2019)

Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid
por: Lorenz, Lisa, et al.
Publicado: (2019)

Pembrolizumab-associated tumor development in a patient with Sézary syndrome
por: Malachowski, Stephen J., et al.
Publicado: (2019)

An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab
por: Bell, Sarah G., et al.
Publicado: (2021)

Metastatic Invasive Lobular Breast Cancer Presenting Clinically with Esophageal Dysphagia
por: Karapetyan, Lilit, et al.
Publicado: (2017)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Immunotherapy in Melanoma: Recent Advances and Future Directions
por: Knight, Andrew, et al.
Publicado: (2023)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors
por: Naidoo, Jarushka, et al.
Publicado: (2018)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
por: Webb, Mason J, et al.
Publicado: (2023)

Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration
por: Higgs, Emily F, et al.
Publicado: (2022)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020)

The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors
por: Luke, Jason J, et al.
Publicado: (2015)

Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
por: Karrison, Theodore, et al.
Publicado: (2018)

Sarcoidosis and Monoclonal Gammopathy of Undetermined Significance (MGUS): A True Association or Just a Coincidence?
por: Hassanein, Mohamed, et al.
Publicado: (2018)

Spleen cells from young but not old immunized mice eradicate large established cancers
por: Schreiber, Karin, et al.
Publicado: (2012)

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
por: Luke, Jason J., et al.
Publicado: (2023)

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
por: Shah, Shalin, et al.
Publicado: (2017)

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
por: Gadgeel, Shirish, et al.
Publicado: (2022)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Tumor cell p38 inhibition to overcome immunotherapy resistance
por: Luke, Jason J., et al.
Publicado: (2023)

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
por: Tapia, Coya, et al.
Publicado: (2020)

Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients
por: Kim, Hyun Ju, et al.
Publicado: (2019)

Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
por: Villalona-Calero, Miguel A., et al.
Publicado: (2022)

Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab
por: Amagai, Ryo, et al.
Publicado: (2023)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_963oruo68samodfa18tes5utsl